Illinois Governor Bruce Rauner has visited Vetter’s facility in Ravensburg, Germany, accompanied by a delegation of approximately twenty key state and county representatives, including notable Illinois economic institutions and organisations.

Together with Vetter management, the contingent discussed present local and global economic issues affecting manufacturing and trade. The delegation was also given a guided tour of one of the company’s aseptic production sites and its centre for visual inspection and logistics.

Governor Rauner said: “I enjoyed meeting members of the Vetter team and touring their high-quality pharmaceutical manufacturing facility here in the beautiful town of Ravensburg.

“It was exciting to hear about their history and their growth plans for the future. Vetter is an important Illinois corporate citizen and we look forward to supporting their continued success in our state.”

Chairman of Vetter’s advisory board and member of the owner family Udo J Vetter said: “It is a distinct honour that the Governor of Illinois paid a special visit to our German headquarters.

“This visit by such a prestigious delegation of individuals is another confirmation of the successful work and contribution we are making to the US life science industry.”

One of the three Vetter managing directors involved in the gubernatorial meeting, Peter Soelkner, said: “Having the opportunity to discuss the current economic environment is of central importance for future initiatives.

“Also, the opportunity to better understand our individual positions and thoughts as trading partners from both sides of the Atlantic was most beneficial.”

Over the course of the visit, Vetter outlined the status of its site for injectable development services in Skokie, US. The current 37,000ft2 facility at the Illinois Science+Technology Park is presently undergoing a further expansion of more than 12,000ft2, which includes storage areas and office space. This expansion is due to the continuous increase in customer demand and increase in project work within the early clinical development of injectables.

In addition, Vetter reviewed its future plans for the company’s Des Plaines property. The pharmaceutical service provider completed the purchase of the 18-acre site in Des Plaines in 2017 as an integral part of the company’s ‘one-stop shopping’ initiative, enabling a fast project start-up upon completion of cooperation agreements with customers. Initial renovations at the site are complete, and office spaces for Vetter’s US key account management, human resources and Legal departments were equipped and is now ready for use.